The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA grants Orphan Drug Designation to STRO-001 for the treatment of multiple myeloma

Oct 17, 2018

On 12 October 2018, the  US Food and Drug Administration (FDA) granted Orphan Drug Designation to STRO-001, a first-in-class antibody-drug conjugate (ADC), for the treatment of patients with multiple myeloma (MM). 1

CD74, a transmembrane glycoprotein involved in the formation and transport of MHC proteins, has been reported to have a high expression in up to 90% of B-cell malignancies, including MM, with minimal expression in normal tissues.  STRO-001 is a novel ADC targeting CD74 glycoprotein. Preclinical data have shown that STRO-001 demonstrates a potent cytotoxicity in MM cell lines and reduces tumor burden in MM xenograft models, including significant prolongation of survival in the MM.1S model. 2

A first-in-human phase I, open-label, multicenter, dose-escalation study  ( NCT03424603) evaluating the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies including MM and non-Hodgkin lymphoma who are refractory to, or intolerant of all established therapy known to provide clinical benefit for their conditions is currently ongoing.

  1. PR Newswire: Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma. 2018 Oct 12.[Accessed 2018 Oct 16].
  2. Embry M. et al. Targeting CD74 in multiple myeloma with a novel antibody-drug conjugate(ADC), STRO-001. Abstract #P328. 2017 Congress of the European Hematology Association.